drugset
Drugs / Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)
last change Jan 2021 re-read 2 minutes ago

Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

Vaccine

Developed for
human papilloma virus infection
Investigated by
Beijing Health Guard Biotechnology, Inc · Jiangsu Province Centers for Disease Control and Prevention · Nanjing Sangruisi pharmtech Ltd. · National Institutes for Food and Drug Control, China · Shanghai Canming pharmtech Ltd.

Trials 1 · a red edge is where a trial was stopped

today NCT05694728 · Ph 2
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05694728 May → Dec 2020 human papilloma virus infection Beijing Health Guard Biotechnology, Inc Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) ClinicalTrials.gov intervention name — accepted as the source's own label NCT05694728 ↗
Modality Vaccine “investigational vaccine” NCT05694728 ↗